#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Ageing is a naturally occurring physiological process which is characterized by both physical and cognitive decline .
2-1	16-22	Ageing	event	new	coref	2-3[3_0]
2-2	23-25	is	_	_	_	_
2-3	26-27	a	event[3]	giv[3]	coref	4-1[0_3]
2-4	28-37	naturally	event[3]	giv[3]	_	_
2-5	38-47	occurring	event[3]	giv[3]	_	_
2-6	48-61	physiological	event[3]	giv[3]	_	_
2-7	62-69	process	event[3]	giv[3]	_	_
2-8	70-75	which	event[3]	giv[3]	_	_
2-9	76-78	is	event[3]	giv[3]	_	_
2-10	79-92	characterized	event[3]	giv[3]	_	_
2-11	93-95	by	event[3]	giv[3]	_	_
2-12	96-100	both	event[3]|event[4]	giv[3]|new[4]	coref	5-27[35_4]
2-13	101-109	physical	event[3]|event[4]	giv[3]|new[4]	_	_
2-14	110-113	and	event[3]|event[4]	giv[3]|new[4]	_	_
2-15	114-123	cognitive	event[3]|event[4]	giv[3]|new[4]	_	_
2-16	124-131	decline	event[3]|event[4]	giv[3]|new[4]	_	_
2-17	132-133	.	_	_	_	_

#Text=Changes are seen in brain neurochemistry as well as in neuroanatomical structures , which negatively affect synaptic plasticity and contribute to atrophy .
3-1	134-141	Changes	abstract	new	coref	4-20[16_0]
3-2	142-145	are	_	_	_	_
3-3	146-150	seen	_	_	_	_
3-4	151-153	in	_	_	_	_
3-5	154-159	brain	object|abstract[7]	new|new[7]	coref	5-8
3-6	160-174	neurochemistry	abstract[7]	new[7]	_	_
3-7	175-177	as	abstract[7]	new[7]	_	_
3-8	178-182	well	abstract[7]	new[7]	_	_
3-9	183-185	as	abstract[7]	new[7]	_	_
3-10	186-188	in	abstract[7]	new[7]	_	_
3-11	189-204	neuroanatomical	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-12	205-215	structures	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-13	216-217	,	abstract[7]	new[7]	_	_
3-14	218-223	which	abstract[7]	new[7]	_	_
3-15	224-234	negatively	abstract[7]	new[7]	_	_
3-16	235-241	affect	abstract[7]	new[7]	_	_
3-17	242-250	synaptic	abstract[7]|abstract[9]	new[7]|new[9]	_	_
3-18	251-261	plasticity	abstract[7]|abstract[9]	new[7]|new[9]	_	_
3-19	262-265	and	abstract[7]	new[7]	_	_
3-20	266-276	contribute	abstract[7]	new[7]	_	_
3-21	277-279	to	_	_	_	_
3-22	280-287	atrophy	abstract	new	_	_
3-23	288-289	.	_	_	_	_

#Text=Ageing is also associated with increased vulnerability of the neurons to oxidative stress , emphasizing the potential importance of changes in the concentration of neurotrophic factors such as a decrease in the concentrations of brain-derived neurotrophic factor ( BDNF ) , which supports the growth and maintenance of neurons .
4-1	290-296	Ageing	event	giv	coref	21-1
4-2	297-299	is	_	_	_	_
4-3	300-304	also	_	_	_	_
4-4	305-315	associated	_	_	_	_
4-5	316-320	with	_	_	_	_
4-6	321-330	increased	abstract[12]	new[12]	_	_
4-7	331-344	vulnerability	abstract[12]	new[12]	_	_
4-8	345-347	of	abstract[12]	new[12]	_	_
4-9	348-351	the	abstract[12]|animal[13]	new[12]|new[13]	coref	4-49[0_13]
4-10	352-359	neurons	abstract[12]|animal[13]	new[12]|new[13]	_	_
4-11	360-362	to	abstract[12]	new[12]	_	_
4-12	363-372	oxidative	abstract[12]|abstract[14]	new[12]|new[14]	coref	5-19[33_14]
4-13	373-379	stress	abstract[12]|abstract[14]	new[12]|new[14]	_	_
4-14	380-381	,	_	_	_	_
4-15	382-393	emphasizing	_	_	_	_
4-16	394-397	the	abstract[15]	new[15]	_	_
4-17	398-407	potential	abstract[15]	new[15]	_	_
4-18	408-418	importance	abstract[15]	new[15]	_	_
4-19	419-421	of	abstract[15]	new[15]	_	_
4-20	422-429	changes	abstract[15]|abstract[16]	new[15]|giv[16]	_	_
4-21	430-432	in	abstract[15]|abstract[16]	new[15]|giv[16]	_	_
4-22	433-436	the	abstract[15]|abstract[16]|abstract[17]	new[15]|giv[16]|new[17]	_	_
4-23	437-450	concentration	abstract[15]|abstract[16]|abstract[17]	new[15]|giv[16]|new[17]	_	_
4-24	451-453	of	abstract[15]|abstract[16]|abstract[17]	new[15]|giv[16]|new[17]	_	_
4-25	454-466	neurotrophic	abstract[15]|abstract[16]|abstract[17]|abstract[18]	new[15]|giv[16]|new[17]|new[18]	coref	5-4[27_18]
4-26	467-474	factors	abstract[15]|abstract[16]|abstract[17]|abstract[18]	new[15]|giv[16]|new[17]|new[18]	_	_
4-27	475-479	such	abstract[15]|abstract[16]|abstract[17]|abstract[18]	new[15]|giv[16]|new[17]|new[18]	_	_
4-28	480-482	as	abstract[15]|abstract[16]|abstract[17]|abstract[18]	new[15]|giv[16]|new[17]|new[18]	_	_
4-29	483-484	a	abstract[15]|abstract[16]|abstract[17]|abstract[18]|event[19]	new[15]|giv[16]|new[17]|new[18]|new[19]	_	_
4-30	485-493	decrease	abstract[15]|abstract[16]|abstract[17]|abstract[18]|event[19]	new[15]|giv[16]|new[17]|new[18]|new[19]	_	_
4-31	494-496	in	abstract[15]|abstract[16]|abstract[17]|abstract[18]|event[19]	new[15]|giv[16]|new[17]|new[18]|new[19]	_	_
4-32	497-500	the	abstract[15]|abstract[16]|abstract[17]|abstract[18]|event[19]|animal[20]	new[15]|giv[16]|new[17]|new[18]|new[19]|new[20]	_	_
4-33	501-515	concentrations	abstract[15]|abstract[16]|abstract[17]|abstract[18]|event[19]|animal[20]	new[15]|giv[16]|new[17]|new[18]|new[19]|new[20]	_	_
4-34	516-518	of	abstract[15]|abstract[16]|abstract[17]|abstract[18]|event[19]|animal[20]	new[15]|giv[16]|new[17]|new[18]|new[19]|new[20]	_	_
4-35	519-532	brain-derived	abstract[15]|abstract[16]|abstract[17]|abstract[18]|event[19]|animal[20]|abstract[21]	new[15]|giv[16]|new[17]|new[18]|new[19]|new[20]|new[21]	appos	4-39[0_21]
4-36	533-545	neurotrophic	abstract[15]|abstract[16]|abstract[17]|abstract[18]|event[19]|animal[20]|abstract[21]	new[15]|giv[16]|new[17]|new[18]|new[19]|new[20]|new[21]	_	_
4-37	546-552	factor	abstract[15]|abstract[16]|abstract[17]|abstract[18]|event[19]|animal[20]|abstract[21]	new[15]|giv[16]|new[17]|new[18]|new[19]|new[20]|new[21]	_	_
4-38	553-554	(	_	_	_	_
4-39	555-559	BDNF	abstract	giv	_	_
4-40	560-561	)	_	_	_	_
4-41	562-563	,	_	_	_	_
4-42	564-569	which	_	_	_	_
4-43	570-578	supports	_	_	_	_
4-44	579-582	the	event[23]	new[23]	_	_
4-45	583-589	growth	event[23]	new[23]	_	_
4-46	590-593	and	_	_	_	_
4-47	594-605	maintenance	abstract[24]	new[24]	_	_
4-48	606-608	of	abstract[24]	new[24]	_	_
4-49	609-616	neurons	abstract[24]|animal	new[24]|giv	_	_
4-50	617-618	.	_	_	_	_

#Text=Decreased concentrations of such neurotrophic factors render brain cells more prone to damage caused by inflammatory processes and oxidative stress , which are key events in age-associated cognitive decline and neurodegenerative disease pathogenesis experienced by many older adults .
5-1	619-628	Decreased	substance[26]	new[26]	coref	22-14[182_26]
5-2	629-643	concentrations	substance[26]	new[26]	_	_
5-3	644-646	of	substance[26]	new[26]	_	_
5-4	647-651	such	substance[26]|abstract[27]	new[26]|giv[27]	coref	10-5[66_27]
5-5	652-664	neurotrophic	substance[26]|abstract[27]	new[26]|giv[27]	_	_
5-6	665-672	factors	substance[26]|abstract[27]	new[26]|giv[27]	_	_
5-7	673-679	render	_	_	_	_
5-8	680-685	brain	object|object[29]	giv|new[29]	coref	11-13
5-9	686-691	cells	object[29]	new[29]	_	_
5-10	692-696	more	_	_	_	_
5-11	697-702	prone	_	_	_	_
5-12	703-705	to	_	_	_	_
5-13	706-712	damage	event[30]	new[30]	coref	12-33[94_30]
5-14	713-719	caused	event[30]	new[30]	_	_
5-15	720-722	by	event[30]	new[30]	_	_
5-16	723-735	inflammatory	event[30]|abstract[31]	new[30]|new[31]	coref	13-13[101_31]
5-17	736-745	processes	event[30]|abstract[31]	new[30]|new[31]	_	_
5-18	746-749	and	event[30]	new[30]	_	_
5-19	750-759	oxidative	event[30]|abstract|abstract[33]	new[30]|new|giv[33]	coref|coref	8-15[54_33]|20-22
5-20	760-766	stress	event[30]|abstract[33]	new[30]|giv[33]	_	_
5-21	767-768	,	event[30]	new[30]	_	_
5-22	769-774	which	event[30]|event[34]	new[30]|new[34]	_	_
5-23	775-778	are	event[30]|event[34]	new[30]|new[34]	_	_
5-24	779-782	key	event[30]|event[34]	new[30]|new[34]	_	_
5-25	783-789	events	event[30]|event[34]	new[30]|new[34]	_	_
5-26	790-792	in	event[30]|event[34]	new[30]|new[34]	_	_
5-27	793-807	age-associated	event[30]|event[34]|event[35]	new[30]|new[34]|giv[35]	coref	6-14[42_35]
5-28	808-817	cognitive	event[30]|event[34]|event[35]	new[30]|new[34]|giv[35]	_	_
5-29	818-825	decline	event[30]|event[34]|event[35]	new[30]|new[34]|giv[35]	_	_
5-30	826-829	and	event[30]|event[34]	new[30]|new[34]	_	_
5-31	830-847	neurodegenerative	event[30]|event[34]|abstract[36]|abstract[37]	new[30]|new[34]|new[36]|new[37]	ana	6-4[0_37]
5-32	848-855	disease	event[30]|event[34]|abstract[36]|abstract[37]	new[30]|new[34]|new[36]|new[37]	_	_
5-33	856-868	pathogenesis	event[30]|event[34]|abstract[37]	new[30]|new[34]|new[37]	_	_
5-34	869-880	experienced	event[30]|event[34]|abstract[37]	new[30]|new[34]|new[37]	_	_
5-35	881-883	by	event[30]|event[34]|abstract[37]	new[30]|new[34]|new[37]	_	_
5-36	884-888	many	event[30]|event[34]|abstract[37]|person[38]	new[30]|new[34]|new[37]|new[38]	coref	22-38[189_38]
5-37	889-894	older	event[30]|event[34]|abstract[37]|person[38]	new[30]|new[34]|new[37]|new[38]	_	_
5-38	895-901	adults	event[30]|event[34]|abstract[37]|person[38]	new[30]|new[34]|new[37]|new[38]	_	_
5-39	902-903	.	_	_	_	_

#Text=In fact , it is estimated that dementia , a far-end result of cognitive decline , affects approximately 50 million people worldwide .
6-1	904-906	In	_	_	_	_
6-2	907-911	fact	_	_	_	_
6-3	912-913	,	_	_	_	_
6-4	914-916	it	abstract	giv	_	_
6-5	917-919	is	_	_	_	_
6-6	920-929	estimated	_	_	_	_
6-7	930-934	that	_	_	_	_
6-8	935-943	dementia	abstract	new	appos	6-10[41_0]
6-9	944-945	,	_	_	_	_
6-10	946-947	a	abstract[41]	giv[41]	coref	8-1[0_41]
6-11	948-955	far-end	abstract[41]	giv[41]	_	_
6-12	956-962	result	abstract[41]	giv[41]	_	_
6-13	963-965	of	abstract[41]	giv[41]	_	_
6-14	966-975	cognitive	abstract[41]|event[42]	giv[41]|giv[42]	_	_
6-15	976-983	decline	abstract[41]|event[42]	giv[41]|giv[42]	_	_
6-16	984-985	,	_	_	_	_
6-17	986-993	affects	_	_	_	_
6-18	994-1007	approximately	person[43]	new[43]	_	_
6-19	1008-1010	50	person[43]	new[43]	_	_
6-20	1011-1018	million	person[43]	new[43]	_	_
6-21	1019-1025	people	person[43]	new[43]	_	_
6-22	1026-1035	worldwide	_	_	_	_
6-23	1036-1037	.	_	_	_	_

#Text=This number is expected to increase to 75 million by 2030 and 132 million by 2050 , posing a considerable burden on the health care system .
7-1	1038-1042	This	abstract[44]	new[44]	_	_
7-2	1043-1049	number	abstract[44]	new[44]	_	_
7-3	1050-1052	is	_	_	_	_
7-4	1053-1061	expected	_	_	_	_
7-5	1062-1064	to	_	_	_	_
7-6	1065-1073	increase	_	_	_	_
7-7	1074-1076	to	_	_	_	_
7-8	1077-1079	75	_	_	_	_
7-9	1080-1087	million	_	_	_	_
7-10	1088-1090	by	_	_	_	_
7-11	1091-1095	2030	time	new	coref	10-22
7-12	1096-1099	and	_	_	_	_
7-13	1100-1103	132	_	_	_	_
7-14	1104-1111	million	_	_	_	_
7-15	1112-1114	by	_	_	_	_
7-16	1115-1119	2050	time	new	_	_
7-17	1120-1121	,	_	_	_	_
7-18	1122-1128	posing	_	_	_	_
7-19	1129-1130	a	abstract[47]	new[47]	_	_
7-20	1131-1143	considerable	abstract[47]	new[47]	_	_
7-21	1144-1150	burden	abstract[47]	new[47]	_	_
7-22	1151-1153	on	abstract[47]	new[47]	_	_
7-23	1154-1157	the	abstract[47]|abstract[49]	new[47]|new[49]	_	_
7-24	1158-1164	health	abstract[47]|abstract[48]|abstract[49]	new[47]|new[48]|new[49]	_	_
7-25	1165-1169	care	abstract[47]|abstract[48]|abstract[49]	new[47]|new[48]|new[49]	_	_
7-26	1170-1176	system	abstract[47]|abstract[49]	new[47]|new[49]	_	_
7-27	1177-1178	.	_	_	_	_

#Text=Dementia is intrinsically linked with depression , as both are characterized by neuroinflammation and oxidative stress .
8-1	1179-1187	Dementia	abstract	giv	coref	9-35
8-2	1188-1190	is	_	_	_	_
8-3	1191-1204	intrinsically	_	_	_	_
8-4	1205-1211	linked	_	_	_	_
8-5	1212-1216	with	_	_	_	_
8-6	1217-1227	depression	abstract	new	ana	8-9
8-7	1228-1229	,	_	_	_	_
8-8	1230-1232	as	_	_	_	_
8-9	1233-1237	both	abstract	giv	coref	9-1
8-10	1238-1241	are	_	_	_	_
8-11	1242-1255	characterized	_	_	_	_
8-12	1256-1258	by	_	_	_	_
8-13	1259-1276	neuroinflammation	abstract	new	_	_
8-14	1277-1280	and	_	_	_	_
8-15	1281-1290	oxidative	abstract[54]	giv[54]	coref	18-20[148_54]
8-16	1291-1297	stress	abstract[54]	giv[54]	_	_
8-17	1298-1299	.	_	_	_	_

#Text=Depression is a complex disease involving a chronic low-grade inflammatory response , activation of cell-mediated immunity , and progressive neuropathology , which can lead to neurodegeneration and later on contribute toward the development of dementia .
9-1	1300-1310	Depression	abstract	giv	coref	9-3[56_0]
9-2	1311-1313	is	_	_	_	_
9-3	1314-1315	a	abstract[56]	giv[56]	coref	10-11[0_56]
9-4	1316-1323	complex	abstract[56]	giv[56]	_	_
9-5	1324-1331	disease	abstract[56]	giv[56]	_	_
9-6	1332-1341	involving	abstract[56]	giv[56]	_	_
9-7	1342-1343	a	abstract[56]|abstract[57]	giv[56]|new[57]	coref	12-13[88_57]
9-8	1344-1351	chronic	abstract[56]|abstract[57]	giv[56]|new[57]	_	_
9-9	1352-1361	low-grade	abstract[56]|abstract[57]	giv[56]|new[57]	_	_
9-10	1362-1374	inflammatory	abstract[56]|abstract[57]	giv[56]|new[57]	_	_
9-11	1375-1383	response	abstract[56]|abstract[57]	giv[56]|new[57]	_	_
9-12	1384-1385	,	abstract[56]	giv[56]	_	_
9-13	1386-1396	activation	abstract[56]|event[58]	giv[56]|new[58]	_	_
9-14	1397-1399	of	abstract[56]|event[58]	giv[56]|new[58]	_	_
9-15	1400-1413	cell-mediated	abstract[56]|event[58]|abstract[59]	giv[56]|new[58]|new[59]	_	_
9-16	1414-1422	immunity	abstract[56]|event[58]|abstract[59]	giv[56]|new[58]|new[59]	_	_
9-17	1423-1424	,	abstract[56]	giv[56]	_	_
9-18	1425-1428	and	abstract[56]	giv[56]	_	_
9-19	1429-1440	progressive	abstract[56]|abstract[60]	giv[56]|new[60]	_	_
9-20	1441-1455	neuropathology	abstract[56]|abstract[60]	giv[56]|new[60]	_	_
9-21	1456-1457	,	abstract[56]|abstract[60]	giv[56]|new[60]	_	_
9-22	1458-1463	which	abstract[56]|abstract[60]	giv[56]|new[60]	_	_
9-23	1464-1467	can	abstract[56]|abstract[60]	giv[56]|new[60]	_	_
9-24	1468-1472	lead	abstract[56]|abstract[60]	giv[56]|new[60]	_	_
9-25	1473-1475	to	abstract[56]|abstract[60]	giv[56]|new[60]	_	_
9-26	1476-1493	neurodegeneration	abstract[56]|abstract[60]|abstract	giv[56]|new[60]|new	coref	11-29
9-27	1494-1497	and	abstract[56]|abstract[60]	giv[56]|new[60]	_	_
9-28	1498-1503	later	abstract[56]|abstract[60]	giv[56]|new[60]	_	_
9-29	1504-1506	on	abstract[56]|abstract[60]	giv[56]|new[60]	_	_
9-30	1507-1517	contribute	abstract[56]|abstract[60]	giv[56]|new[60]	_	_
9-31	1518-1524	toward	_	_	_	_
9-32	1525-1528	the	event[62]	new[62]	_	_
9-33	1529-1540	development	event[62]	new[62]	_	_
9-34	1541-1543	of	event[62]	new[62]	_	_
9-35	1544-1552	dementia	event[62]|abstract	new[62]|giv	coref	10-9
9-36	1553-1554	.	_	_	_	_

#Text=Besides being one of many risk factors for dementia , depression is estimated to be the leading cause of disability by 2030 .
10-1	1555-1562	Besides	_	_	_	_
10-2	1563-1568	being	_	_	_	_
10-3	1569-1572	one	abstract[64]	new[64]	_	_
10-4	1573-1575	of	abstract[64]	new[64]	_	_
10-5	1576-1580	many	abstract[64]|abstract[66]	new[64]|giv[66]	coref	22-25[185_66]
10-6	1581-1585	risk	abstract[64]|abstract|abstract[66]	new[64]|new|giv[66]	coref	17-10[132_0]
10-7	1586-1593	factors	abstract[64]|abstract[66]	new[64]|giv[66]	_	_
10-8	1594-1597	for	abstract[64]|abstract[66]	new[64]|giv[66]	_	_
10-9	1598-1606	dementia	abstract[64]|abstract[66]|abstract	new[64]|giv[66]|giv	coref	14-35
10-10	1607-1608	,	_	_	_	_
10-11	1609-1619	depression	abstract	giv	coref	17-33
10-12	1620-1622	is	_	_	_	_
10-13	1623-1632	estimated	_	_	_	_
10-14	1633-1635	to	_	_	_	_
10-15	1636-1638	be	_	_	_	_
10-16	1639-1642	the	abstract[69]	new[69]	_	_
10-17	1643-1650	leading	abstract[69]	new[69]	_	_
10-18	1651-1656	cause	abstract[69]	new[69]	_	_
10-19	1657-1659	of	abstract[69]	new[69]	_	_
10-20	1660-1670	disability	abstract[69]|abstract	new[69]|new	_	_
10-21	1671-1673	by	_	_	_	_
10-22	1674-1678	2030	time	giv	_	_
10-23	1679-1680	.	_	_	_	_

#Text=Metal ions such as copper and zinc play an essential role in brain function and neuronal homeostasis , and long-term imbalance of these metals has been linked to neurodegeneration and neurological disorder .
11-1	1681-1686	Metal	person|substance[73]	new|new[73]	_	_
11-2	1687-1691	ions	substance[73]	new[73]	_	_
11-3	1692-1696	such	substance[73]	new[73]	_	_
11-4	1697-1699	as	substance[73]	new[73]	_	_
11-5	1700-1706	copper	substance[73]|substance|substance[75]	new[73]|new|new[75]	coref|coref	13-1|19-11[154_75]
11-6	1707-1710	and	substance[73]|substance[75]	new[73]|new[75]	_	_
11-7	1711-1715	zinc	substance[73]|substance[75]|substance	new[73]|new[75]|new	coref	15-5
11-8	1716-1720	play	_	_	_	_
11-9	1721-1723	an	abstract[77]	new[77]	coref	18-9[144_77]
11-10	1724-1733	essential	abstract[77]	new[77]	_	_
11-11	1734-1738	role	abstract[77]	new[77]	_	_
11-12	1739-1741	in	abstract[77]	new[77]	_	_
11-13	1742-1747	brain	abstract[77]|object|abstract[79]	new[77]|giv|new[79]	coref|coref	12-18[89_0]|22-28[186_79]
11-14	1748-1756	function	abstract[77]|abstract[79]	new[77]|new[79]	_	_
11-15	1757-1760	and	abstract[77]	new[77]	_	_
11-16	1761-1769	neuronal	abstract[77]|abstract[80]	new[77]|new[80]	_	_
11-17	1770-1781	homeostasis	abstract[77]|abstract[80]	new[77]|new[80]	_	_
11-18	1782-1783	,	_	_	_	_
11-19	1784-1787	and	_	_	_	_
11-20	1788-1797	long-term	abstract[81]	new[81]	_	_
11-21	1798-1807	imbalance	abstract[81]	new[81]	_	_
11-22	1808-1810	of	abstract[81]	new[81]	_	_
11-23	1811-1816	these	abstract[81]|substance[82]	new[81]|new[82]	coref	19-21[158_82]
11-24	1817-1823	metals	abstract[81]|substance[82]	new[81]|new[82]	_	_
11-25	1824-1827	has	_	_	_	_
11-26	1828-1832	been	_	_	_	_
11-27	1833-1839	linked	_	_	_	_
11-28	1840-1842	to	_	_	_	_
11-29	1843-1860	neurodegeneration	abstract	giv	_	_
11-30	1861-1864	and	_	_	_	_
11-31	1865-1877	neurological	abstract[84]	new[84]	ana	12-1[0_84]
11-32	1878-1886	disorder	abstract[84]	new[84]	_	_
11-33	1887-1888	.	_	_	_	_

#Text=It is thought that this may be due to the provocation of an unchecked immune response within the brain via the increased production of reactive oxygen species , which can lead to brain damage via the upregulation of inflammatory mediators .
12-1	1889-1891	It	abstract	giv	ana	12-5
12-2	1892-1894	is	_	_	_	_
12-3	1895-1902	thought	_	_	_	_
12-4	1903-1907	that	_	_	_	_
12-5	1908-1912	this	abstract	giv	_	_
12-6	1913-1916	may	_	_	_	_
12-7	1917-1919	be	_	_	_	_
12-8	1920-1923	due	_	_	_	_
12-9	1924-1926	to	_	_	_	_
12-10	1927-1930	the	event[87]	new[87]	_	_
12-11	1931-1942	provocation	event[87]	new[87]	_	_
12-12	1943-1945	of	event[87]	new[87]	_	_
12-13	1946-1948	an	event[87]|abstract[88]	new[87]|giv[88]	_	_
12-14	1949-1958	unchecked	event[87]|abstract[88]	new[87]|giv[88]	_	_
12-15	1959-1965	immune	event[87]|abstract[88]	new[87]|giv[88]	_	_
12-16	1966-1974	response	event[87]|abstract[88]	new[87]|giv[88]	_	_
12-17	1975-1981	within	event[87]|abstract[88]	new[87]|giv[88]	_	_
12-18	1982-1985	the	event[87]|abstract[88]|object[89]	new[87]|giv[88]|giv[89]	coref	12-33[0_89]
12-19	1986-1991	brain	event[87]|abstract[88]|object[89]	new[87]|giv[88]|giv[89]	_	_
12-20	1992-1995	via	event[87]	new[87]	_	_
12-21	1996-1999	the	event[87]|abstract[90]	new[87]|new[90]	_	_
12-22	2000-2009	increased	event[87]|abstract[90]	new[87]|new[90]	_	_
12-23	2010-2020	production	event[87]|abstract[90]	new[87]|new[90]	_	_
12-24	2021-2023	of	event[87]|abstract[90]	new[87]|new[90]	_	_
12-25	2024-2032	reactive	event[87]|abstract[90]|substance[91]|plant[92]	new[87]|new[90]|new[91]|new[92]	_	_
12-26	2033-2039	oxygen	event[87]|abstract[90]|substance[91]|plant[92]	new[87]|new[90]|new[91]|new[92]	_	_
12-27	2040-2047	species	event[87]|abstract[90]|plant[92]	new[87]|new[90]|new[92]	_	_
12-28	2048-2049	,	event[87]|abstract[90]|plant[92]	new[87]|new[90]|new[92]	_	_
12-29	2050-2055	which	event[87]|abstract[90]|plant[92]	new[87]|new[90]|new[92]	_	_
12-30	2056-2059	can	event[87]|abstract[90]|plant[92]	new[87]|new[90]|new[92]	_	_
12-31	2060-2064	lead	event[87]|abstract[90]|plant[92]	new[87]|new[90]|new[92]	_	_
12-32	2065-2067	to	event[87]|abstract[90]|plant[92]	new[87]|new[90]|new[92]	_	_
12-33	2068-2073	brain	event[87]|abstract[90]|plant[92]|object|event[94]	new[87]|new[90]|new[92]|giv|giv[94]	coref	14-16[110_0]
12-34	2074-2080	damage	event[87]|abstract[90]|plant[92]|event[94]	new[87]|new[90]|new[92]|giv[94]	_	_
12-35	2081-2084	via	event[87]|abstract[90]|plant[92]	new[87]|new[90]|new[92]	_	_
12-36	2085-2088	the	event[87]|abstract[90]|plant[92]|event[95]	new[87]|new[90]|new[92]|new[95]	_	_
12-37	2089-2101	upregulation	event[87]|abstract[90]|plant[92]|event[95]	new[87]|new[90]|new[92]|new[95]	_	_
12-38	2102-2104	of	event[87]|abstract[90]|plant[92]|event[95]	new[87]|new[90]|new[92]|new[95]	_	_
12-39	2105-2117	inflammatory	event[87]|abstract[90]|plant[92]|event[95]|person[96]	new[87]|new[90]|new[92]|new[95]|new[96]	_	_
12-40	2118-2127	mediators	event[87]|abstract[90]|plant[92]|event[95]|person[96]	new[87]|new[90]|new[92]|new[95]|new[96]	_	_
12-41	2128-2129	.	_	_	_	_

#Text=Copper is an essential transition metal that acts as a catalyst for several biological processes such as the synthesis of neurotransmitters .
13-1	2130-2136	Copper	substance	giv	coref	13-3[99_0]
13-2	2137-2139	is	_	_	_	_
13-3	2140-2142	an	substance[99]	giv[99]	coref	15-1[0_99]
13-4	2143-2152	essential	substance[99]	giv[99]	_	_
13-5	2153-2163	transition	event|substance[99]	new|giv[99]	_	_
13-6	2164-2169	metal	substance[99]	giv[99]	_	_
13-7	2170-2174	that	substance[99]	giv[99]	_	_
13-8	2175-2179	acts	substance[99]	giv[99]	_	_
13-9	2180-2182	as	substance[99]	giv[99]	_	_
13-10	2183-2184	a	substance[99]|substance[100]	giv[99]|new[100]	_	_
13-11	2185-2193	catalyst	substance[99]|substance[100]	giv[99]|new[100]	_	_
13-12	2194-2197	for	substance[99]|substance[100]	giv[99]|new[100]	_	_
13-13	2198-2205	several	substance[99]|substance[100]|abstract[101]	giv[99]|new[100]|giv[101]	coref	16-7[123_101]
13-14	2206-2216	biological	substance[99]|substance[100]|abstract[101]	giv[99]|new[100]|giv[101]	_	_
13-15	2217-2226	processes	substance[99]|substance[100]|abstract[101]	giv[99]|new[100]|giv[101]	_	_
13-16	2227-2231	such	substance[99]|substance[100]|abstract[101]	giv[99]|new[100]|giv[101]	_	_
13-17	2232-2234	as	substance[99]|substance[100]|abstract[101]	giv[99]|new[100]|giv[101]	_	_
13-18	2235-2238	the	substance[99]|substance[100]|abstract[101]|event[102]	giv[99]|new[100]|giv[101]|new[102]	_	_
13-19	2239-2248	synthesis	substance[99]|substance[100]|abstract[101]|event[102]	giv[99]|new[100]|giv[101]|new[102]	_	_
13-20	2249-2251	of	substance[99]|substance[100]|abstract[101]|event[102]	giv[99]|new[100]|giv[101]|new[102]	_	_
13-21	2252-2269	neurotransmitters	substance[99]|substance[100]|abstract[101]|event[102]|abstract	giv[99]|new[100]|giv[101]|new[102]|new	_	_
13-22	2270-2271	.	_	_	_	_

#Text=However , disturbance of its transport , causing accumulation in the blood and depletion in the brain , has been linked with neurodegenerative diseases such as Alzheimer ’s , the most common form of dementia .
14-1	2272-2279	However	_	_	_	_
14-2	2280-2281	,	_	_	_	_
14-3	2282-2293	disturbance	event[104]	new[104]	ana	14-5[0_104]
14-4	2294-2296	of	event[104]	new[104]	_	_
14-5	2297-2300	its	event[104]|event|abstract[106]	new[104]|giv|new[106]	_	_
14-6	2301-2310	transport	event[104]|abstract[106]	new[104]|new[106]	_	_
14-7	2311-2312	,	event[104]	new[104]	_	_
14-8	2313-2320	causing	event[104]	new[104]	_	_
14-9	2321-2333	accumulation	event[104]|abstract[107]	new[104]|new[107]	_	_
14-10	2334-2336	in	event[104]|abstract[107]	new[104]|new[107]	_	_
14-11	2337-2340	the	event[104]|abstract[107]|substance[108]	new[104]|new[107]|new[108]	_	_
14-12	2341-2346	blood	event[104]|abstract[107]|substance[108]	new[104]|new[107]|new[108]	_	_
14-13	2347-2350	and	event[104]	new[104]	_	_
14-14	2351-2360	depletion	event[104]|event[109]	new[104]|new[109]	_	_
14-15	2361-2363	in	event[104]|event[109]	new[104]|new[109]	_	_
14-16	2364-2367	the	event[104]|event[109]|object[110]	new[104]|new[109]|giv[110]	_	_
14-17	2368-2373	brain	event[104]|event[109]|object[110]	new[104]|new[109]|giv[110]	_	_
14-18	2374-2375	,	_	_	_	_
14-19	2376-2379	has	_	_	_	_
14-20	2380-2384	been	_	_	_	_
14-21	2385-2391	linked	_	_	_	_
14-22	2392-2396	with	_	_	_	_
14-23	2397-2414	neurodegenerative	abstract[111]	new[111]	_	_
14-24	2415-2423	diseases	abstract[111]	new[111]	_	_
14-25	2424-2428	such	abstract[111]	new[111]	_	_
14-26	2429-2431	as	abstract[111]	new[111]	_	_
14-27	2432-2441	Alzheimer	abstract[111]|abstract[112]	new[111]|new[112]	appos	14-30[113_112]
14-28	2442-2444	’s	abstract[111]|abstract[112]	new[111]|new[112]	_	_
14-29	2445-2446	,	_	_	_	_
14-30	2447-2450	the	abstract[113]	giv[113]	_	_
14-31	2451-2455	most	abstract[113]	giv[113]	_	_
14-32	2456-2462	common	abstract[113]	giv[113]	_	_
14-33	2463-2467	form	abstract[113]	giv[113]	_	_
14-34	2468-2470	of	abstract[113]	giv[113]	_	_
14-35	2471-2479	dementia	abstract[113]|abstract	giv[113]|giv	coref	17-13
14-36	2480-2481	.	_	_	_	_

#Text=Copper works synergistically with zinc in several metalloenzymes , such as the antioxidant enzyme superoxide dismutase .
15-1	2482-2488	Copper	substance	giv	coref	16-19
15-2	2489-2494	works	_	_	_	_
15-3	2495-2510	synergistically	_	_	_	_
15-4	2511-2515	with	_	_	_	_
15-5	2516-2520	zinc	substance	giv	coref	16-1
15-6	2521-2523	in	_	_	_	_
15-7	2524-2531	several	substance[117]	new[117]	_	_
15-8	2532-2546	metalloenzymes	substance[117]	new[117]	_	_
15-9	2547-2548	,	substance[117]	new[117]	_	_
15-10	2549-2553	such	substance[117]	new[117]	_	_
15-11	2554-2556	as	substance[117]	new[117]	_	_
15-12	2557-2560	the	substance[117]|substance[118]	new[117]|new[118]	_	_
15-13	2561-2572	antioxidant	substance[117]|substance[118]	new[117]|new[118]	_	_
15-14	2573-2579	enzyme	substance[117]|substance[118]	new[117]|new[118]	_	_
15-15	2580-2590	superoxide	substance|object[120]	new|new[120]	_	_
15-16	2591-2600	dismutase	object[120]	new[120]	_	_
15-17	2601-2602	.	_	_	_	_

#Text=Zinc is an essential component of numerous biochemical and molecular processes related to cell survival and , unlike copper , has very low toxicity in humans .
16-1	2603-2607	Zinc	substance	giv	coref	16-3[122_0]
16-2	2608-2610	is	_	_	_	_
16-3	2611-2613	an	substance[122]	giv[122]	coref	17-6[0_122]
16-4	2614-2623	essential	substance[122]	giv[122]	_	_
16-5	2624-2633	component	substance[122]	giv[122]	_	_
16-6	2634-2636	of	substance[122]	giv[122]	_	_
16-7	2637-2645	numerous	substance[122]|abstract[123]	giv[122]|giv[123]	_	_
16-8	2646-2657	biochemical	substance[122]|abstract[123]	giv[122]|giv[123]	_	_
16-9	2658-2661	and	substance[122]|abstract[123]	giv[122]|giv[123]	_	_
16-10	2662-2671	molecular	substance[122]|abstract[123]	giv[122]|giv[123]	_	_
16-11	2672-2681	processes	substance[122]|abstract[123]	giv[122]|giv[123]	_	_
16-12	2682-2689	related	substance[122]|abstract[123]	giv[122]|giv[123]	_	_
16-13	2690-2692	to	substance[122]|abstract[123]	giv[122]|giv[123]	_	_
16-14	2693-2697	cell	substance[122]|abstract[123]|place|event[125]	giv[122]|giv[123]|new|new[125]	_	_
16-15	2698-2706	survival	substance[122]|abstract[123]|event[125]	giv[122]|giv[123]|new[125]	_	_
16-16	2707-2710	and	_	_	_	_
16-17	2711-2712	,	_	_	_	_
16-18	2713-2719	unlike	_	_	_	_
16-19	2720-2726	copper	substance	giv	coref	18-3
16-20	2727-2728	,	_	_	_	_
16-21	2729-2732	has	_	_	_	_
16-22	2733-2737	very	abstract[127]	new[127]	_	_
16-23	2738-2741	low	abstract[127]	new[127]	_	_
16-24	2742-2750	toxicity	abstract[127]	new[127]	_	_
16-25	2751-2753	in	_	_	_	_
16-26	2754-2760	humans	animal	new	_	_
16-27	2761-2762	.	_	_	_	_

#Text=However , research suggests that zinc deficiency may increase the risk of dementia , and thus supplementation with zinc may improve cognition and regulation of emotional behavior ( such as anger and depression ) in cognitively intact individuals .
17-1	2763-2770	However	_	_	_	_
17-2	2771-2772	,	_	_	_	_
17-3	2773-2781	research	abstract	new	_	_
17-4	2782-2790	suggests	_	_	_	_
17-5	2791-2795	that	_	_	_	_
17-6	2796-2800	zinc	substance|abstract[131]	giv|new[131]	coref	17-19
17-7	2801-2811	deficiency	abstract[131]	new[131]	_	_
17-8	2812-2815	may	_	_	_	_
17-9	2816-2824	increase	_	_	_	_
17-10	2825-2828	the	abstract[132]	giv[132]	_	_
17-11	2829-2833	risk	abstract[132]	giv[132]	_	_
17-12	2834-2836	of	abstract[132]	giv[132]	_	_
17-13	2837-2845	dementia	abstract[132]|abstract	giv[132]|giv	coref	21-21
17-14	2846-2847	,	_	_	_	_
17-15	2848-2851	and	_	_	_	_
17-16	2852-2856	thus	_	_	_	_
17-17	2857-2872	supplementation	substance[134]	new[134]	_	_
17-18	2873-2877	with	substance[134]	new[134]	_	_
17-19	2878-2882	zinc	substance[134]|substance	new[134]|giv	coref	18-1
17-20	2883-2886	may	_	_	_	_
17-21	2887-2894	improve	_	_	_	_
17-22	2895-2904	cognition	abstract	new	_	_
17-23	2905-2908	and	_	_	_	_
17-24	2909-2919	regulation	abstract[137]	new[137]	_	_
17-25	2920-2922	of	abstract[137]	new[137]	_	_
17-26	2923-2932	emotional	abstract[137]|abstract[138]	new[137]|new[138]	_	_
17-27	2933-2941	behavior	abstract[137]|abstract[138]	new[137]|new[138]	_	_
17-28	2942-2943	(	abstract[137]|abstract[138]	new[137]|new[138]	_	_
17-29	2944-2948	such	abstract[137]|abstract[138]	new[137]|new[138]	_	_
17-30	2949-2951	as	abstract[137]|abstract[138]	new[137]|new[138]	_	_
17-31	2952-2957	anger	abstract[137]|abstract[138]|abstract	new[137]|new[138]|new	_	_
17-32	2958-2961	and	abstract[137]|abstract[138]	new[137]|new[138]	_	_
17-33	2962-2972	depression	abstract[137]|abstract[138]|abstract	new[137]|new[138]|giv	coref	18-13[146_0]
17-34	2973-2974	)	abstract[137]|abstract[138]	new[137]|new[138]	_	_
17-35	2975-2977	in	_	_	_	_
17-36	2978-2989	cognitively	person[141]	new[141]	coref	21-19[174_141]
17-37	2990-2996	intact	person[141]	new[141]	_	_
17-38	2997-3008	individuals	person[141]	new[141]	_	_
17-39	3009-3010	.	_	_	_	_

#Text=Zinc and copper are also likely to have a synergistic role in Alzheimer ’s disease , with copper promoting oxidative stress and displacing zinc from body tissues .
18-1	3011-3015	Zinc	substance	giv	coref	18-24
18-2	3016-3019	and	_	_	_	_
18-3	3020-3026	copper	substance	giv	coref	18-18
18-4	3027-3030	are	_	_	_	_
18-5	3031-3035	also	_	_	_	_
18-6	3036-3042	likely	_	_	_	_
18-7	3043-3045	to	_	_	_	_
18-8	3046-3050	have	_	_	_	_
18-9	3051-3052	a	abstract[144]	giv[144]	_	_
18-10	3053-3064	synergistic	abstract[144]	giv[144]	_	_
18-11	3065-3069	role	abstract[144]	giv[144]	_	_
18-12	3070-3072	in	abstract[144]	giv[144]	_	_
18-13	3073-3082	Alzheimer	abstract[144]|person[145]|abstract[146]	giv[144]|new[145]|giv[146]	_	_
18-14	3083-3085	’s	abstract[144]|person[145]|abstract[146]	giv[144]|new[145]|giv[146]	_	_
18-15	3086-3093	disease	abstract[144]|abstract[146]	giv[144]|giv[146]	_	_
18-16	3094-3095	,	_	_	_	_
18-17	3096-3100	with	_	_	_	_
18-18	3101-3107	copper	substance	giv	coref	19-11
18-19	3108-3117	promoting	_	_	_	_
18-20	3118-3127	oxidative	abstract[148]	giv[148]	coref	20-22[167_148]
18-21	3128-3134	stress	abstract[148]	giv[148]	_	_
18-22	3135-3138	and	_	_	_	_
18-23	3139-3149	displacing	_	_	_	_
18-24	3150-3154	zinc	substance	giv	coref	19-13[155_0]
18-25	3155-3159	from	_	_	_	_
18-26	3160-3164	body	object|object[151]	new|new[151]	_	_
18-27	3165-3172	tissues	object[151]	new[151]	_	_
18-28	3173-3174	.	_	_	_	_

#Text=Therefore , not only is the individual nutritional status of copper and zinc of concern , but the balance between these two metals appears to be important .
19-1	3175-3184	Therefore	_	_	_	_
19-2	3185-3186	,	_	_	_	_
19-3	3187-3190	not	_	_	_	_
19-4	3191-3195	only	_	_	_	_
19-5	3196-3198	is	_	_	_	_
19-6	3199-3202	the	abstract[152]	new[152]	coref	21-5[171_152]
19-7	3203-3213	individual	abstract[152]	new[152]	_	_
19-8	3214-3225	nutritional	abstract[152]	new[152]	_	_
19-9	3226-3232	status	abstract[152]	new[152]	_	_
19-10	3233-3235	of	abstract[152]	new[152]	_	_
19-11	3236-3242	copper	abstract[152]|substance|substance[154]	new[152]|giv|giv[154]	coref	20-8[160_0]
19-12	3243-3246	and	abstract[152]|substance[154]	new[152]|giv[154]	_	_
19-13	3247-3251	zinc	abstract[152]|substance[154]|substance[155]	new[152]|giv[154]|giv[155]	coref	20-10[0_155]
19-14	3252-3254	of	abstract[152]|substance[154]|substance[155]	new[152]|giv[154]|giv[155]	_	_
19-15	3255-3262	concern	abstract[152]|substance[154]|substance[155]|abstract	new[152]|giv[154]|giv[155]|new	_	_
19-16	3263-3264	,	_	_	_	_
19-17	3265-3268	but	_	_	_	_
19-18	3269-3272	the	abstract[157]	new[157]	_	_
19-19	3273-3280	balance	abstract[157]	new[157]	_	_
19-20	3281-3288	between	abstract[157]	new[157]	_	_
19-21	3289-3294	these	abstract[157]|substance[158]	new[157]|giv[158]	_	_
19-22	3295-3298	two	abstract[157]|substance[158]	new[157]|giv[158]	_	_
19-23	3299-3305	metals	abstract[157]|substance[158]	new[157]|giv[158]	_	_
19-24	3306-3313	appears	_	_	_	_
19-25	3314-3316	to	_	_	_	_
19-26	3317-3319	be	_	_	_	_
19-27	3320-3329	important	_	_	_	_
19-28	3330-3331	.	_	_	_	_

#Text=Indeed , studies suggest that calculating the copper to zinc ratio ( Cu/Zn ratio ) provides valuable information in regard to oxidative stress and inflammatory responses .
20-1	3332-3338	Indeed	_	_	_	_
20-2	3339-3340	,	_	_	_	_
20-3	3341-3348	studies	abstract	new	_	_
20-4	3349-3356	suggest	_	_	_	_
20-5	3357-3361	that	_	_	_	_
20-6	3362-3373	calculating	_	_	_	_
20-7	3374-3377	the	abstract[162]	new[162]	appos	20-13[164_162]
20-8	3378-3384	copper	substance[160]|abstract[162]	giv[160]|new[162]	coref	22-11[179_160]
20-9	3385-3387	to	substance[160]|abstract[162]	giv[160]|new[162]	_	_
20-10	3388-3392	zinc	substance[160]|substance|abstract[162]	giv[160]|giv|new[162]	coref	21-6
20-11	3393-3398	ratio	abstract[162]	new[162]	_	_
20-12	3399-3400	(	_	_	_	_
20-13	3401-3406	Cu/Zn	abstract|abstract[164]	new|giv[164]	coref|coref	21-11|21-9[173_164]
20-14	3407-3412	ratio	abstract[164]	giv[164]	_	_
20-15	3413-3414	)	_	_	_	_
20-16	3415-3423	provides	_	_	_	_
20-17	3424-3432	valuable	abstract[165]	new[165]	_	_
20-18	3433-3444	information	abstract[165]	new[165]	_	_
20-19	3445-3447	in	_	_	_	_
20-20	3448-3454	regard	_	_	_	_
20-21	3455-3457	to	_	_	_	_
20-22	3458-3467	oxidative	abstract|abstract[167]	giv|giv[167]	_	_
20-23	3468-3474	stress	abstract[167]	giv[167]	_	_
20-24	3475-3478	and	_	_	_	_
20-25	3479-3491	inflammatory	abstract[168]	new[168]	_	_
20-26	3492-3501	responses	abstract[168]	new[168]	_	_
20-27	3502-3503	.	_	_	_	_

#Text=Ageing is associated with decreased zinc status and hence increased Cu/Zn ratio , which is also observed in individuals with dementia .
21-1	3504-3510	Ageing	event	giv	_	_
21-2	3511-3513	is	_	_	_	_
21-3	3514-3524	associated	_	_	_	_
21-4	3525-3529	with	_	_	_	_
21-5	3530-3539	decreased	abstract[171]	giv[171]	_	_
21-6	3540-3544	zinc	substance|abstract[171]	giv|giv[171]	coref	22-14[181_0]
21-7	3545-3551	status	abstract[171]	giv[171]	_	_
21-8	3552-3555	and	_	_	_	_
21-9	3556-3561	hence	abstract[173]	giv[173]	coref	22-21[184_173]
21-10	3562-3571	increased	abstract[173]	giv[173]	_	_
21-11	3572-3577	Cu/Zn	abstract|abstract[173]	giv|giv[173]	coref	22-22
21-12	3578-3583	ratio	abstract[173]	giv[173]	_	_
21-13	3584-3585	,	abstract[173]	giv[173]	_	_
21-14	3586-3591	which	abstract[173]	giv[173]	_	_
21-15	3592-3594	is	abstract[173]	giv[173]	_	_
21-16	3595-3599	also	abstract[173]	giv[173]	_	_
21-17	3600-3608	observed	abstract[173]	giv[173]	_	_
21-18	3609-3611	in	abstract[173]	giv[173]	_	_
21-19	3612-3623	individuals	abstract[173]|person[174]	giv[173]|giv[174]	_	_
21-20	3624-3628	with	abstract[173]|person[174]	giv[173]|giv[174]	_	_
21-21	3629-3637	dementia	abstract[173]|person[174]|abstract	giv[173]|giv[174]|giv	_	_
21-22	3638-3639	.	_	_	_	_

#Text=Therefore , this study aimed to investigate the relationship between plasma copper and serum zinc concentrations , as well as the Cu/Zn ratio , neurotrophic factors , cognitive function , and psychological distress in a sample of Australian community-dwelling older adults .
22-1	3640-3649	Therefore	_	_	_	_
22-2	3650-3651	,	_	_	_	_
22-3	3652-3656	this	abstract[176]	new[176]	_	_
22-4	3657-3662	study	abstract[176]	new[176]	_	_
22-5	3663-3668	aimed	_	_	_	_
22-6	3669-3671	to	_	_	_	_
22-7	3672-3683	investigate	_	_	_	_
22-8	3684-3687	the	abstract[177]	new[177]	_	_
22-9	3688-3700	relationship	abstract[177]	new[177]	_	_
22-10	3701-3708	between	abstract[177]	new[177]	_	_
22-11	3709-3715	plasma	abstract[177]|object|substance[179]	new[177]|new|giv[179]	_	_
22-12	3716-3722	copper	abstract[177]|substance[179]	new[177]|giv[179]	_	_
22-13	3723-3726	and	_	_	_	_
22-14	3727-3732	serum	object|substance[181]|substance[182]	new|giv[181]|giv[182]	_	_
22-15	3733-3737	zinc	substance[181]|substance[182]	giv[181]|giv[182]	_	_
22-16	3738-3752	concentrations	substance[182]	giv[182]	_	_
22-17	3753-3754	,	_	_	_	_
22-18	3755-3757	as	_	_	_	_
22-19	3758-3762	well	_	_	_	_
22-20	3763-3765	as	_	_	_	_
22-21	3766-3769	the	abstract[184]	giv[184]	_	_
22-22	3770-3775	Cu/Zn	abstract|abstract[184]	giv|giv[184]	_	_
22-23	3776-3781	ratio	abstract[184]	giv[184]	_	_
22-24	3782-3783	,	_	_	_	_
22-25	3784-3796	neurotrophic	abstract[185]	giv[185]	_	_
22-26	3797-3804	factors	abstract[185]	giv[185]	_	_
22-27	3805-3806	,	_	_	_	_
22-28	3807-3816	cognitive	abstract[186]	giv[186]	_	_
22-29	3817-3825	function	abstract[186]	giv[186]	_	_
22-30	3826-3827	,	_	_	_	_
22-31	3828-3831	and	_	_	_	_
22-32	3832-3845	psychological	abstract[187]	new[187]	_	_
22-33	3846-3854	distress	abstract[187]	new[187]	_	_
22-34	3855-3857	in	_	_	_	_
22-35	3858-3859	a	person[188]	new[188]	_	_
22-36	3860-3866	sample	person[188]	new[188]	_	_
22-37	3867-3869	of	person[188]	new[188]	_	_
22-38	3870-3880	Australian	person[188]|person[189]	new[188]|giv[189]	_	_
22-39	3881-3899	community-dwelling	person[188]|person[189]	new[188]|giv[189]	_	_
22-40	3900-3905	older	person[188]|person[189]	new[188]|giv[189]	_	_
22-41	3906-3912	adults	person[188]|person[189]	new[188]|giv[189]	_	_
22-42	3913-3914	.	_	_	_	_
